How does Vandetanib stop thyroid cancer from growing?
Vandetanib blocks two key proteins (RET and VEGFR kinases) that cancer cells use to grow and spread. In clinical trials, it slowed cancer growth in 45–53% of patients with advanced thyroid cancer, with a median progression-free survival of 19+ months [4][5].
Vandetanib is a tyrosine kinase inhibitor (TKI)—a targeted drug that acts like a molecular brake on cancer cell engines. In the ZETA trial (2012), 331 patients with metastatic medullary thyroid cancer received either Vandetanib 300 mg daily or placebo; the Vandetanib group had a median progression-free survival of 30.5 months versus 19.3 months in the placebo group [5]. This 11-month survival advantage proved the drug's power in slowing disease.
Inside cancer cells, RET and VEGFR proteins send growth signals that tell the cell to divide and spread. Vandetanib enters the cell and blocks these signals, like turning off a light switch. Your body then recognizes the cancer cell as damaged and removes it through natural immune processes. This mechanism works best in cancers with RET mutations or VEGFR overexpression—your oncologist will have tested your tumor for these mutations before prescribing [4].
In real-world practice, Vandetanib works best when you take it consistently every day at the same time. Missing doses or stopping early can allow cancer cells to restart their growth signals. Most patients tolerate 300 mg daily, but if diarrhea or QT prolongation develops, your oncologist may reduce the dose to 200 mg—which still provides meaningful benefit while reducing side effects [8].
Set a daily phone alarm for your Vandetanib dose (morning or evening—pick whichever you'll remember). Keep a simple calendar to track any new rashes, diarrhea, or chest discomfort, and bring it to your oncology visits. This helps your doctor spot patterns and adjust your dose before problems become serious.